Rathbones Group PLC - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 49 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Rathbones Group PLC ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$337,598
-15.7%
432,8180.0%0.00%
-50.0%
Q2 2023$400,356
-15.1%
432,8180.0%0.00%
-20.0%
Q1 2023$471,771
-25.3%
432,8180.0%0.01%
-28.6%
Q4 2022$631,914
+35.9%
432,8180.0%0.01%
+16.7%
Q3 2022$465,000
-36.8%
432,8180.0%0.01%
-25.0%
Q2 2022$736,000
-17.5%
432,8180.0%0.01%
-11.1%
Q1 2022$892,000
-45.0%
432,8180.0%0.01%
-43.8%
Q4 2021$1,623,000
-27.5%
432,818
-0.0%
0.02%
-33.3%
Q3 2021$2,238,000
+21.4%
432,9210.0%0.02%
+20.0%
Q2 2021$1,844,000
-19.8%
432,9210.0%0.02%
-31.0%
Q1 2021$2,299,000
-1.5%
432,9210.0%0.03%
-12.1%
Q4 2020$2,333,000
-32.5%
432,9210.0%0.03%
-44.1%
Q3 2020$3,455,000
-22.1%
432,921
-2.3%
0.06%
-34.4%
Q2 2020$4,434,000
+308.7%
442,921
+11.0%
0.09%
+181.2%
Q1 2020$1,085,000
+28.7%
398,853
-43.2%
0.03%
+45.5%
Q4 2019$843,000
-20.5%
702,5750.0%0.02%
-26.7%
Q3 2019$1,061,000
-62.5%
702,575
-0.3%
0.03%
-66.3%
Q2 2019$2,832,000
+130.4%
704,472
+146.6%
0.09%
+122.5%
Q1 2019$1,229,000
-4.4%
285,722
+27.9%
0.04%
-18.4%
Q4 2018$1,285,000
-57.6%
223,4300.0%0.05%
-52.4%
Q3 2018$3,030,000
+4.8%
223,430
-8.2%
0.10%
-5.5%
Q2 2018$2,890,000
+5.7%
243,4300.0%0.11%
-1.8%
Q1 2018$2,734,000
+30.8%
243,430
-22.2%
0.11%
+30.6%
Q4 2017$2,090,000
-20.5%
312,930
-2.5%
0.08%
-25.4%
Q3 2017$2,629,000
+192.1%
321,050
+60.1%
0.11%
+185.0%
Q2 2017$900,000
-18.6%
200,5250.0%0.04%
-20.0%
Q1 2017$1,105,000
+36.1%
200,5250.0%0.05%
+22.0%
Q4 2016$812,000
-65.1%
200,525
-39.3%
0.04%
-65.8%
Q3 2016$2,327,000
-36.6%
330,125
-26.7%
0.12%
-40.6%
Q2 2016$3,672,000
+125.3%
450,525
+124.7%
0.20%
+104.0%
Q1 2016$1,630,000
+7.7%
200,5250.0%0.10%
+3.1%
Q4 2015$1,514,000200,5250.10%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q1 2016
NameSharesValueWeighting ↓
NEA Management Company, LLC 15,832,611$68,080,0003.54%
Matrix Capital Management Company, LP 28,000,000$120,400,0003.21%
Virtus ETF Advisers LLC 50,655$218,0000.46%
TFG Asset Management GP Ltd 500,000$2,150,0000.27%
Rock Springs Capital Management LP 800,000$3,440,0000.13%
Orbimed Advisors 1,350,655$5,808,0000.09%
Vident Investment Advisory, LLC 289,340$1,244,0000.07%
WS MANAGEMENT LLLP 185,537$798,0000.05%
Rathbones Group PLC 285,722$1,229,0000.04%
Tekla Capital Management LLC 228,496$983,0000.04%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders